RxDoctor Payments Data

Jennifer Imel, APRN

Family · Minneola, KSNPI 1437775574

Payments from drug & device makers

$1,073in general payments, 2019–2025

Across 47 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$450
  • AbbVie$236
  • Phathom Pharmaceuticals, Inc.$121
  • Lilly USA, LLC$67
  • Organon$64
  • Novo Nordisk$55
  • plus $79 from 4 others

What the payments were for

  • Food & beverage$1,073100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,073 in reported general payments places this provider in the 75th percentile of 1,579 family providers in Kansas.

See all family providers in Kansas

Medicare billing

Part B allowed, 2024
$1,789
Medicare patients
15
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide13$12,875
Tresiba Flextouch U-100Insulin Degludec13$11,002
EliquisApixaban12$9,607
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,114
LantusInsulin Glargine,hum.Rec.Anlog19$1,283
SynthroidLevothyroxine Sodium11$1,256
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,022
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$958
Divalproex Sodium11$897
Pregabalin16$779
Duloxetine Hcl37$737
Levothyroxine Sodium77$722
Albuterol Sulfate HfaAlbuterol Sulfate43$689
Fluvoxamine Maleate14$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$67$12,87513 claims
AstraZenecaBreztri Aerosphere$450$8,11513 claims
AbbVieSynthroid$236$1,25611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,579 family providers in Kansas.

Other family in Minneola

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →